C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.